PMC:7441788 / 21398-22434 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T191","span":{"begin":186,"end":187},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T192","span":{"begin":198,"end":199},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T193","span":{"begin":323,"end":324},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T194","span":{"begin":335,"end":336},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T195","span":{"begin":526,"end":527},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. This study include a large, random sample from 25 metropolitan New York hospitals. The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome. Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders. The dosing in the doses and frequencies of HCQ and azithromycin varied greatly. The confidence intervals for some of the findings are wide."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T252","span":{"begin":82,"end":94},"obj":"Chemical"},{"id":"T253","span":{"begin":286,"end":288},"obj":"Chemical"},{"id":"T254","span":{"begin":375,"end":387},"obj":"Chemical"},{"id":"T255","span":{"begin":948,"end":960},"obj":"Chemical"}],"attributes":[{"id":"A252","pred":"chebi_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A253","pred":"chebi_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"},{"id":"A254","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A255","pred":"chebi_id","subj":"T255","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":"Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. This study include a large, random sample from 25 metropolitan New York hospitals. The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome. Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders. The dosing in the doses and frequencies of HCQ and azithromycin varied greatly. The confidence intervals for some of the findings are wide."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T142","span":{"begin":82,"end":94},"obj":"Chemical"},{"id":"T143","span":{"begin":375,"end":387},"obj":"Chemical"},{"id":"T144","span":{"begin":948,"end":960},"obj":"Chemical"}],"attributes":[{"id":"A142","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A143","pred":"chebi_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"},{"id":"A144","pred":"chebi_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":"Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. This study include a large, random sample from 25 metropolitan New York hospitals. The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome. Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders. The dosing in the doses and frequencies of HCQ and azithromycin varied greatly. The confidence intervals for some of the findings are wide."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T161","span":{"begin":0,"end":506},"obj":"Sentence"},{"id":"T162","span":{"begin":507,"end":589},"obj":"Sentence"},{"id":"T163","span":{"begin":590,"end":754},"obj":"Sentence"},{"id":"T164","span":{"begin":755,"end":896},"obj":"Sentence"},{"id":"T165","span":{"begin":897,"end":976},"obj":"Sentence"},{"id":"T166","span":{"begin":977,"end":1036},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. This study include a large, random sample from 25 metropolitan New York hospitals. The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome. Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders. The dosing in the doses and frequencies of HCQ and azithromycin varied greatly. The confidence intervals for some of the findings are wide."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T66","span":{"begin":854,"end":859},"obj":"http://purl.obolibrary.org/obo/GO_0016265"}],"text":"Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. This study include a large, random sample from 25 metropolitan New York hospitals. The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome. Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders. The dosing in the doses and frequencies of HCQ and azithromycin varied greatly. The confidence intervals for some of the findings are wide."}

{"project":"LitCovid-sentences","denotations":[{"id":"T161","span":{"begin":0,"end":506},"obj":"Sentence"},{"id":"T162","span":{"begin":507,"end":589},"obj":"Sentence"},{"id":"T163","span":{"begin":590,"end":754},"obj":"Sentence"},{"id":"T164","span":{"begin":755,"end":896},"obj":"Sentence"},{"id":"T165","span":{"begin":897,"end":976},"obj":"Sentence"},{"id":"T166","span":{"begin":977,"end":1036},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Rosenberg et al[60] Retrospective multicenter cohort study HCQ group:n = 271;HCQ ＋azithromycin group:n = 735control group:n = 221 HCQ:200 mg/400 mg/600 mg/other/unknown, frequency: once a day/twice a day/other/unknownazithromycin:200 mg/250 mg/400 mg/500 mg/other/unknown, methods:Oral/IV/unknown,frequency: only once/once a day/twice a day/other/unknown Treatment with HCQ, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. This study include a large, random sample from 25 metropolitan New York hospitals. The sample was drawnearly in the epidemic to include patients with long, complicated, and ongoing hospital stays; In-hospital mortality was used as primary outcome. Retrospective study design; There may be missing information; Mortality was limited to in-hospital death; There may be potential confounders. The dosing in the doses and frequencies of HCQ and azithromycin varied greatly. The confidence intervals for some of the findings are wide."}